Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 14/20 | 0.56 |
| ▸ | HSD11B2 | P80365 | 3/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1223056 | 0.86 | HSD11B1 (0.56) | HSD11B1HSD11B2OPRD1KCNH2 | |
| SCHEMBL3656302 | 0.85 | HSD11B1 (0.42) | HSD11B1HSD11B2 | |
| SCHEMBL1223122 | 0.84 | HSD11B1 (0.53) | HSD11B1HSD11B2OPRD1KCNH2 | |
| SCHEMBL1222605 | 0.82 | HSD11B1 (0.80) | HSD11B1HSD11B2 | |
| SCHEMBL1222483 | 0.82 | HSD11B1 (0.43) | HSD11B1HSD11B2EGFRCACNA1G | |
| SCHEMBL1223443 | 0.82 | HSD11B1 (0.59) | HSD11B1HSD11B2 | |
| SCHEMBL3742454 | 0.78 | HSD11B1 (0.44) | HSD11B1HSD11B2 | |
| SCHEMBL1223445 | 0.78 | HSD11B1 (0.53) | HSD11B1HSD11B2 | |
| SCHEMBL3809943 | 0.76 | HSD11B1 (0.58) | HSD11B1HSD11B2 | |
| SCHEMBL1222317 | 0.76 | HSD11B1 (0.58) | HSD11B1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927715-B2 | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 | VITAE PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | claimed |
| US-8927715-B2 | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 | VITAE PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20110034455-A1 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
| EP-2064187-A2 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | Vitae Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008024497-A2 | INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034455-A1 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885HSD11B2 3/4885EGFR 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.